Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

Objective Common single nucleotide polymorphisms in the SORL1 gene have been associated with late onset Alzheimer disease (LOAD), but causal variants have not been fully characterized nor has the mechanism been established. The study was undertaken to identify functional SORL1 mutations in patients with LOAD. Methods This was a family- and cohort-based genetic association study.

Key findings

Why it matters

This family- and cohort-based genetic association study identified coding mutations in the SORL1 gene in patients with late-onset Alzheimer's disease. It is genetic research and does not test any treatment, cure, or prevention.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of neurology)
Journal's citation record 3 / 4 Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 191 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 14.7 citations a year over 13 year(s) since 2015
Impact for its field and year 4 / 6 Cited 10.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 17 other studies in this library
Still being cited 2 / 4 Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Richard P Mayeux: h-index 158 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Cambridge: institution h-index 1,973 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25382023)
Free to read 0 / 2 Behind a paywall — scores zero
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Vardarajan, B. N., Zhang, Y., Lee, J. H., Cheng, R., Bohm, C., Ghani, M., et al. (2015). Coding mutations in SORL1 and Alzheimer disease. Annals of neurology. https://doi.org/10.1002/ana.24305

Vancouver

Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, et al. Coding mutations in SORL1 and Alzheimer disease. Annals of neurology. 2015. doi:10.1002/ana.24305. PMID: 25382023.

BibTeX

@article{vardarajan2015-25382023,
  author  = {Vardarajan, B. N. and Zhang, Y. and Lee, J. H. and Cheng, R. and Bohm, C. and Ghani, M. and Reitz, C. and Reyes-Dumeyer, D. and others},
  title   = {{Coding mutations in SORL1 and Alzheimer disease}},
  journal = {Annals of neurology},
  year    = {2015},
  doi     = {10.1002/ana.24305},
  pmid    = {25382023},
  url     = {https://doi.org/10.1002/ana.24305}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk genes beyond APOE

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →